Abstract 6108
Background
Colorectal cancer (CRC) is one of the most common cancers worldwide, and the third most common cancer in Korea. Although the number of Korean CRC survivors is estimated over 220,000, we have insufficient survivorship care program to improve survival and quality of life (QoL) of CRC survivors.
Methods
We started to build a prospective cohort on October, 2016, and collected clinicopathological and social factors from 265 Korean CRC survivors in Cancer Prevention Center, Yonsei Cancer Center, Seoul, Republic of Korea. Health-related QoL (HRQOL) was assessed using EORTC-QLQ C30, CR29, ELD14, CIPN20, and EQ-VAS in 189 CRC survivors.
Results
Median duration of cancer survivorship was 70.7 months (range, 0.7-209.8), and 80 patients (42.3%) was long term CRC survivor (who live with cancer more than 5 years). In terms of HRQOL, median scale was 63.4 (standard deviation [SD], ±21.2) for global health, 81.7 (±15.3) for function, and 19.1 (±14.7) for symptom in all CRC survivors. Symptom scale was higher in the long-term survivors (21.8 vs. 17.1; P = 0.040), and in female patients (21.4 vs. 15.3; P = 0.006). Higher stage of disease (III or IV) was related to higher symptom scale (21.6 vs. 17.2; P = 0.042), and lower functional scale (78.2 vs. 84.3; P = 0.005). Frequently reported late effects were fatigue, insomnia, flatulence, bloated feeling, defecation problem, urinary frequency, sexual dysfunction in male, and sensory neuropathy. Insomnia (P = 0.018), sexual dysfunction in male (P = 0.003), and sensory neuropathy (P = 0.043) were significantly correlated with lower HRQOL scales. In the patients who were treated with oxaliplatin (n = 41), chemotherapy-induced neuropathy is related to worse global health (hazard ratio [HR], -3.29; 95% confidence interval [CI], -8.34- -2.0; P = 0.002).
Conclusions
Various late effects are found in CRC survivors, and late effects may worsen the HRQOL of Korean CRC survivors. We are developing personalized and integrative management programs for CRC survivors.
Clinical trial identification
Legal entity responsible for the study
Yonsei University College of Medicine, Ministry of Health & Welfare, Republic of Korea.
Funding
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1631020).
Editorial Acknowledgement
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1631020).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract